SCHEMBL30983600

SCHEMBL30983600

Cc1cc(OCCCN2CCOCC2)ncc1-c1nc2c(OC3(C)CC3)ncnc2n1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 4/20 0.44
▸ PIK3CD O00329 1/20 0.39
▸ PDE10A Q9Y233 3/20 0.38
▸ SLC6A4 P31645 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ SIGMAR1 Q99720 2/20 0.37
▸ BRD4 O60885 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983552 0.93 PIK3CD (0.40) TLR7PIK3CDSLC6A4HRH3HTR1A
SCHEMBL30983394 0.91 PIK3CD (0.39) TLR7PIK3CDHRH3SIGMAR1HTR1A
SCHEMBL30983871 0.89 PIK3CD (0.41) TLR7PIK3CDHRH3SIGMAR1HTR1A
SCHEMBL30983537 0.89 PIK3CD (0.40) TLR7PIK3CDSIGMAR1BRD4HTR1A
SCHEMBL30983475 0.88 SIGMAR1 (0.40) TLR7PIK3CDSIGMAR1HTR1AHTR7
SCHEMBL30983453 0.87 PIK3CD (0.39) PIK3CDHTR1AHTR7
SCHEMBL30983430 0.87 PIK3CD (0.41) TLR7PIK3CD
SCHEMBL30983607 0.86 PIK3CD (0.41) TLR7PIK3CD
SCHEMBL30983436 0.85 PIK3CD (0.40) TLR7PIK3CDSLC6A4HRH3HTR1A
SCHEMBL30983493 0.84 PIK3CD (0.40) TLR7PIK3CDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB TLR7 4408/4885PIK3CD 434/4885PDE10A 1995/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB TLR7 4408/4885PIK3CD 434/4885PDE10A 1995/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB TLR7 4408/4885PIK3CD 434/4885PDE10A 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback